This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): C326
Description: C326 is a novel protein therapeutic, designed to inhibit the function of interleukin-6 (IL-6), a pro-inflammatory cytokine that stimulates an immune response to trauma and has been shown to play a role in multiple disease indications. By inhibiting IL-6, C326 is designed to reduce or prevent symptoms associated with autoimmunity and inflammation. C326, as an Avimer drug candidate, has a unique structure that distinguishes it from antibodies, antibody fragments and other therapeutic proteins. Avimer proteins are much smaller than most therapeutic proteins and antibodies.
Deal Structure: In September 2006, Amgen entered into a definitive merger agreement to acquire Avidia. The transaction provided Amgen with C326.
Additional information available to subscribers only: